Subscribe To
CLNN / Why Is Clene (CLNN) Stock Soaring 23% Today?
CLNN News
By GlobeNewsWire
August 30, 2023
Clene to Present at Upcoming September Conferences
SALT LAKE CITY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary more_horizontal
By Zacks Investment Research
May 12, 2023
Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates
Clene Inc. (CLNN) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $ more_horizontal
By GlobeNewsWire
March 8, 2023
Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial
Webcast set for 7:30 a.m. ET on March 9 Webcast set for 7:30 a.m. ET on March 9 more_horizontal
By GlobeNewsWire
August 30, 2022
Clene to Present at Upcoming September Investor Conferences
SALT LAKE CITY, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary more_horizontal
By The Motley Fool
July 18, 2022
Why Shares of Clene Jumped 11.8% on Monday
The company's lead therapy has shown progress against ALS in preliminary trials. more_horizontal
By Benzinga
July 18, 2022
HC Wainwright Initiates Coverage On This Nanocrystals Stock
H.C. Wainwright initiated coverage on Clene Inc (NASDAQ: CLNN) with a Buy rating and a $16 price target. Clene is focused on the development of more_horizontal
By InvestorPlace
July 14, 2022
Why Is Clene (CLNN) Stock Soaring 23% Today?
Clene (CLNN) stock is heading higher on Thursday following the release of data from a long-term clinical trial of CNM-Au8. The post Why Is Clene (CLNN more_horizontal